Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIS 3 feasibility study for prevention of late recurrence in ER-positive breast cancer survivors
2014-004430-26Phase 3Terminated
- Sponsor
- Queen Mary University of London
- Start
- Apr 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of anastrozole, exemestane, letrozole, zoledronic acid and metformin in breast cancer (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Primary feasibility endpoint. Started Apr 2015; status: terminated.
02
Drugs
anastrozoleexemestaneletrozolezoledronic acidmetformin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-004430-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004430-26.